These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now. Long GV; Menzies AM; Scolyer RA J Clin Oncol; 2023 Jun; 41(17):3236-3248. PubMed ID: 37104746 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach. Davar D; Tarhini AA; Kirkwood JM Clin Dermatol; 2013; 31(3):237-50. PubMed ID: 23608443 [TBL] [Abstract][Full Text] [Related]